

AMENDMENTS TO THE CLAIMS

Please amend the claims as shown below without prejudice or disclaimer. This claim listing replaces all prior versions and listings.

1-37. Cancelled

38. (Currently amended) An expression vector comprising a nucleic acid sequence CAP(6D)-1,2 ~~as shown in~~ (SEQ ID NO.: 6) and a nucleic acid sequence encoding human B7.1 ~~as illustrated in Figure 12 and SEQ ID NO: 11.~~

39. (Currently amended) The expression vector of claim 38 wherein the human B7.1 sequence is that ~~illustrated in Figure 12 and~~ of SEQ ID NO. 11.

40. (Previously presented) The expression vector of claim 38 wherein the vector is a plasmid or a viral vector.

41. (Previously presented) The expression vector of claim 38 or 39 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.

42. (Previously presented) The expression vector of claim 40 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

43. (Previously presented) The expression vector of claim 41 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

44. (Previously presented) The expression vector of claim 42 further comprising at least one additional tumor associated antigen.

45. (Previously presented) The expression vector of claim 38 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.

46. (Previously presented) An isolated DNA molecule comprising the CAP(6D)-1,2 sequence shown in SEQ ID NO:6 and a nucleotide sequence encoding human B7.1.

47. (Currently amended) The expression vector of claim 46 wherein the human B7.1 sequence is that ~~illustrated in Figure 12 and~~ of SEQ ID NO. 11.

48-50. Cancelled